execut turnov omega integr issu
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data feb
rate updat feb
currenc amount express
valuat growth profit
methodolog valu compani
recent post better result follow weak
stem omega integr issu return brand
competitor like johnson johnson store shelv
competit pressur compani prescript topic
busi previous consid store-brand
market share gain competitor manufactur issu
consum seek lower-cost option recess
unsustain think oper sustain
reason growth even though expect
reset execut turnov remain concern think
resili consum health busi sustain healthi
long term think consum health busi support
stabl growth littl risk reimburs concern
new entrant increas peer like teva
becom focus space on-going market penetr
private-label product intern portfolio expans
over-the-count approv exist prescript drug
help bolster growth prescript segment also
primari driver growth margin expans although
think segment support above-averag profit
prescript topic busi shrunk increas competit
omega deal under-perform tarnish manag
merger acquisit streak still think
compani capital-alloc decis enhanc competit
advantag long-term growth opportun pbm
food drug
sergeant boost access store-brand
pet-car market unlik over-the-counter drug store-brand penetr
market remain rel small like
leverag store-brand retail expertis expand
player european over-the-counter market provid necessari
brand portfolio salesforc compet among
fragment custom base retail region
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
largest store-brand over-the-count pharmaceut
pharmaceut activ pharmaceut ingredi unit
state sell product stock-keep unit
follow acquisit omega pharma approxim
compani revenu come outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit
rais fair valu estim per share
increas growth margin forecast
estim impli forward price-to-earnings multipl
growth fuel mid-single-digit growth
consum health nutrit segment combin
return low-single-digit growth prescript drug
segment follow declin revenu
volum face pressur competit over-the-counter
market modestli intensifi market share gain
store-brand product slow econom condit stabil
reduct sale certain under-perform non-core
asset help stabil profit
dont anticip major futur margin expans
compani consum health nutrit prescript
drug segment probabl continu reli
omega salesforc distribut infrastructur
expand oper throughout europ tax manufactur
administr area offer long-term potenti cost
companywid oper margin eventu rise
back high teen next year
compani make improv integr omega
estim long-term corpor tax rate
remain near assum cost capit
approxim compani
despit rel stabil private-label
consum health busi assign firm high
uncertainti rate due recent volatil gener
prescript topic segment on-going issu
integr omega announc sale tysabri
royalti remov uncertainti cash flow
bull case assum continu share gain
gener over-the-counter market larger new product launch lead
five-year averag organ growth consum
health segment also includ intern sale
growth brand prescript pharmaceut
segment stock price per share scenario
reach oper margin thank
success integr omega better-than-expect
contrast bear-cas scenario assum slow custom
accept store-brand
weak prescript topic busi
greater-than-expect competit price pressur
gener over-the-counter market model low-single-digit growth
across consum health segment nearli zero
growth prescript segment bear-cas
scenario yield fair valu estim per share
chang moat rate none
narrow consid gener drug industri
whole predominantli no-moat industri includ
barrier entri remain low product remain highli
commodit industri remain fairli fragment
despit past consolid consum health
oper previous thought economi
scale shelf space manag uniqu packag
capabl help entrench firm custom suppli
chain addit thought manufactur
regulatori barrier prescript topic segment
could support above-averag growth profit
think continu rise new entrant particularli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
low-cost emerg market continu diminish cost
advantag larger peer like given recent price
eros prescript topic unit combin
poor perform omega asset diminish
confid creat econom profit
long term abil challeng gradual
improv growth profit seen much
recent past probabl difficult sustain
acquisit tysabri royalti histor
made larg portion bottom line
manag announc sale asset earli
think neg econom moat trend
think rel larg exposur over-the-counter gener
drug market threaten erod firm cost advantag
time addit new competit prescript
topic market like continu diminish firm
histori stabl price segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
odifficult econom condit push price-
ojohnson johnson return over-the-counter market
gradual improv economi slow
market share gain store-brand segment
market leader gener releas
prescript drug receiv over-the-counter approv
particip major domest launch
see less sever competit price
pressur topic segment gener drug
industri addit one fourth
gener drug applic first-to-fil statu
grant day market exclus ensur
depress return capit acquisit
live expect overpay asset
remain credibl threat sharehold
recent deal help diversifi
oper major retail wal-
mart repres larg concentr
revenu give compani littl price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
like mani peer specialti pharma industri
appetit acquisit increas financi
leverag year believ cash flow
enabl compani meet financi oblig
includ small dividend gradual reduc debt
burden billion acquisit omega
billion acquisit follow number smaller deal
like sergeant paddock lab
past year push total debt close billion
end manag recent sold tysabri
royalti stream billion cash million
manag use tysabri proce pay
debt current estim net
debt/ebitda reach time end
possess consolid custom base
among larg consolid retail chain wholesal
acquisit omega pharma boost
diversif alon account almost
revenu follow combin omega
estim although undoubtedli firmli embed
custom suppli chain unlik shift anoth
supplier would disastr consequ
low-cost emerging-market competitor
abl success compet
higher-valu store-brand over-the-counter market dont predict
drastic shift market share medium term
earli manag sold tysabri royalti stream
repres signific portion compani
cash flow face new competit product like
ocrelizumab near term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
give standard stewardship rate
papa leav run valeant follow
exit cfo judi brown new ceo john hendrickson
announc retir middl
work transit leadership anoth new ceo
announc hendrickson join
extens leadership experi compani includ
recent presid previous execut vice
presid global oper suppli chain
post perform improv hendrickson
leadership focus sell non-core
under-perform asset well improv integr
effort omega
papa tenur ceo chairman manag
made mostli wise capital-alloc decis
opinion recent paddock lab pbm hold
acquisit came fair price broaden
moat give compani stronghold
high-barrier-to-entri infant nutrit topic drug
market recent deal lower
compani tax rate omega expand oper
europ also help improv competit advantag
concern acquisit could perman
erod return capit dont expect return capit
return compani histor norm anytim soon
under-perform lead impair end
suggest manag may bitten
could chew recent deal
experi moder insid ownership share
appreci portion
compens stem partial return capit
coincid hendrickson start ceo independ
director lauri brla becam chairman board papa
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
previous held ceo chairman role
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
execut expand gener
multist civil investig potenti price collus
among gener manufactur expand number
compani drug examin
particularli surpris see investig broaden --
includ firm like novarti actavi part teva
dr reddi laboratori endo --
specif target presid execut
director rajiv malik may potenti expos
compani greater scrutini
profit prescript topic busi decreas
interest expens recent debt paydown modest
share repurchas despit posit trajectori
busi chang dont materi shift
fair valu estim model especi sinc alreadi
incorpor stabl growth margin improv
consum health segment
meanwhil manag asset sale focu
stabil profit improv financi leverag
thank total expect debt reduct billion
year-end leav no-moat rate place
on-going ambigu extent wrongdo
liabil difficult forecast assum
settlement payment gener manufactur model
doesnt dramat shift fair valu estim
market valu sever gener drug categori
also seem small estim therefor plan leav
fair valu estim unchang time
meantim feasibl investig could lead
higher-level execut turnov previous would
anticip investig remain
concern still view increas competit price
pressur signific long-term hurdl
gener drug industri -- primari reason no-moat
rate pure-play gener firm
still face headwind underli second-
although still long-term concern gener
industri price eros margin stabil report
encourag second-quart result signifi stabil
across busi segment along notabl effort
improv balanc sheet manag slightli increas
year-end revenu adjust ep outlook thank
increas expect new product launch improv
exclud discontinu product line asset sale
expect competit key product underli
growth profit show sign improv
exclud sale vitamin supplement busi
wit growth rel stabl adjust
oper margin strength cough cold
allergi smoke cessat along product launch
includ nexium later year help sustain
perform segment continu mostli
track expect exclud discontinu
unprofit distribut agreement intern
consum health segment also continu report stabl
growth constant currenc margin expans
adjust oper margin nearli basi point
thank on-going restructur cost save
effort includ in-sourc product manufactur
although prescript topic segment continu
face pressur previou competit gener
entocort adjust oper margin quarter
suggest potenti greater stabil
new product launch off-set price eros
remain within manag expect approxim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
